2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report

Angela Yee Moon Wang; Tadao Akizawa; Sunita Bavanandan; Takayuki Hamano; Adrian Liew; Kuo Cheng Lu; Dusit Lumlertgul; Kook Hwan Oh; Ming Hui Zhao; Samuel Ka-Shun Fung; Yoshitsugu Obi; Keiichi Sumida; Lina Hui Lin Choong; Bak Leong Goh; Chuan Ming Hao; Young Joo Kwon; Der Cherng Tarng; Li Zuo; David C. Wheeler; Yusuke Tsukamoto; Masafumi Fukagawa

doi:10.1016/j.ekir.2019.09.007

2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report

Angela Yee Moon Wang, Tadao Akizawa, Sunita Bavanandan, Takayuki Hamano, Adrian Liew, Kuo Cheng Lu, Dusit Lumlertgul, Kook Hwan Oh, Ming Hui Zhao, Samuel Ka-Shun Fung, Yoshitsugu Obi, Keiichi Sumida, Lina Hui Lin Choong, Bak Leong Goh, Chuan Ming Hao, Young Joo Kwon, Der Cherng Tarng, Li Zuo, David C. Wheeler, Yusuke TsukamotoMasafumi Fukagawa

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD) 2009 provided recommendations on the detection, evaluation, and treatment of CKD-MBD in patients CKD who are and are not undergoing dialysis. Because of the accumulation of evidence since this initial publication, the CKD-MBD Guideline underwent a selective update in 2017. In April 2018, KDIGO convened a CKD-MBD Guideline Implementation Summit in Japan with the key objective to discuss various barriers to the uptake and implementation of the CKD-MBD Guideline in 8 Asian countries/regions. These countries/regions were comparable according to their high-to-middle economic ranking assigned by the World Bank. The discussion took into account the availability of CKD-MBD medication therapies and government health policies that may influence reimbursement and practice patterns in the region. Most importantly, Summit participants developed a framework of multifaceted strategies aimed at overcoming barriers to guideline implementation. The Summit attendees suggested a shared decision-making approach between clinicians and patients in CKD-MBD management, as well as individualized care based on the treatment risk-benefit ratio. The Summit participants also discussed how KDIGO, as a guideline development organization, may work in partnership with local and national nephrology societies to provide education and facilitate implementation of the guideline by clinicians. The conclusions drawn from this Summit in Asia may serve as an important guide for other regions to follow.

Original language	English
Pages (from-to)	1523-1537
Number of pages	15
Journal	Kidney International Reports
Volume	4
Issue number	11
DOIs	https://doi.org/10.1016/j.ekir.2019.09.007
Publication status	Published - 2019 Nov

Bibliographical note

Funding Information:
This Summit conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Bayer HealthCare, Boehringer Ingelheim, Chugai Pharmaceutical, Fresenius Medical Care, Japan CKD-MBD Forum, Japanese Society of Nephrology (JSN), Kissei Pharmaceutical, Kyowa Kirin Pharmaceutical Development, Nikkiso, Ono Pharmaceutical, Suntop Healthcare, and Torii Pharmaceutical. We thank Dr. Sinee Disthabanchong for valuable input into this manuscript. Other conference participants are Ali K. Abu-Alfa, Lebanon; Hideki Fujii, Japan; Naohiko Fujii, Japan; Kunitoshi Iseki, Japan; Nobuhiko Joki, Japan; Tilakavati Karupaiah, Malaysia; Naoki Kashihara, Japan; Junichiro Kazama, Japan; Fumihiko Koiwa, Japan; Hirotaka Komaba, Japan; Braden J. Manns, Canada; Masahide Mizobuchi, Japan; Yusuke Sakaguchi, Japan; Hiroko Segawa, Japan; Takashi Shigematsu, Japan; Tetsuo Shoji, Japan; Motoko Tanaka, Japan; Masatomo Taniguchi, Japan; Minako Wakasugi, Japan; and Suguru Yamamoto, Japan.

Publisher Copyright:
© 2019 International Society of Nephrology

Keywords

CKD
KDIGO CKD-MBD Guideline
bone mineral density
calcium
dialysis
hyperparathyroidism
hyperphosphatemia

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.ekir.2019.09.007

Cite this

Wang, A. Y. M., Akizawa, T., Bavanandan, S., Hamano, T., Liew, A., Lu, K. C., Lumlertgul, D., Oh, K. H., Zhao, M. H., Ka-Shun Fung, S., Obi, Y., Sumida, K., Choong, L. H. L., Goh, B. L., Hao, C. M., Kwon, Y. J., Tarng, D. C., Zuo, L., Wheeler, D. C., ... Fukagawa, M. (2019). 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report. Kidney International Reports, 4(11), 1523-1537. https://doi.org/10.1016/j.ekir.2019.09.007

2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report. / Wang, Angela Yee Moon; Akizawa, Tadao; Bavanandan, Sunita et al.
In: Kidney International Reports, Vol. 4, No. 11, 11.2019, p. 1523-1537.

Research output: Contribution to journal › Article › peer-review

Wang, AYM, Akizawa, T, Bavanandan, S, Hamano, T, Liew, A, Lu, KC, Lumlertgul, D, Oh, KH, Zhao, MH, Ka-Shun Fung, S, Obi, Y, Sumida, K, Choong, LHL, Goh, BL, Hao, CM, Kwon, YJ, Tarng, DC, Zuo, L, Wheeler, DC, Tsukamoto, Y & Fukagawa, M 2019, '2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report', Kidney International Reports, vol. 4, no. 11, pp. 1523-1537. https://doi.org/10.1016/j.ekir.2019.09.007

@article{a787b9ed93654fccbd934612a0a5ea97,

title = "2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report",

abstract = "The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD) 2009 provided recommendations on the detection, evaluation, and treatment of CKD-MBD in patients CKD who are and are not undergoing dialysis. Because of the accumulation of evidence since this initial publication, the CKD-MBD Guideline underwent a selective update in 2017. In April 2018, KDIGO convened a CKD-MBD Guideline Implementation Summit in Japan with the key objective to discuss various barriers to the uptake and implementation of the CKD-MBD Guideline in 8 Asian countries/regions. These countries/regions were comparable according to their high-to-middle economic ranking assigned by the World Bank. The discussion took into account the availability of CKD-MBD medication therapies and government health policies that may influence reimbursement and practice patterns in the region. Most importantly, Summit participants developed a framework of multifaceted strategies aimed at overcoming barriers to guideline implementation. The Summit attendees suggested a shared decision-making approach between clinicians and patients in CKD-MBD management, as well as individualized care based on the treatment risk-benefit ratio. The Summit participants also discussed how KDIGO, as a guideline development organization, may work in partnership with local and national nephrology societies to provide education and facilitate implementation of the guideline by clinicians. The conclusions drawn from this Summit in Asia may serve as an important guide for other regions to follow.",

keywords = "CKD, KDIGO CKD-MBD Guideline, bone mineral density, calcium, dialysis, hyperparathyroidism, hyperphosphatemia",

author = "Wang, {Angela Yee Moon} and Tadao Akizawa and Sunita Bavanandan and Takayuki Hamano and Adrian Liew and Lu, {Kuo Cheng} and Dusit Lumlertgul and Oh, {Kook Hwan} and Zhao, {Ming Hui} and {Ka-Shun Fung}, Samuel and Yoshitsugu Obi and Keiichi Sumida and Choong, {Lina Hui Lin} and Goh, {Bak Leong} and Hao, {Chuan Ming} and Kwon, {Young Joo} and Tarng, {Der Cherng} and Li Zuo and Wheeler, {David C.} and Yusuke Tsukamoto and Masafumi Fukagawa",

note = "Funding Information: This Summit conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Bayer HealthCare, Boehringer Ingelheim, Chugai Pharmaceutical, Fresenius Medical Care, Japan CKD-MBD Forum, Japanese Society of Nephrology (JSN), Kissei Pharmaceutical, Kyowa Kirin Pharmaceutical Development, Nikkiso, Ono Pharmaceutical, Suntop Healthcare, and Torii Pharmaceutical. We thank Dr. Sinee Disthabanchong for valuable input into this manuscript. Other conference participants are Ali K. Abu-Alfa, Lebanon; Hideki Fujii, Japan; Naohiko Fujii, Japan; Kunitoshi Iseki, Japan; Nobuhiko Joki, Japan; Tilakavati Karupaiah, Malaysia; Naoki Kashihara, Japan; Junichiro Kazama, Japan; Fumihiko Koiwa, Japan; Hirotaka Komaba, Japan; Braden J. Manns, Canada; Masahide Mizobuchi, Japan; Yusuke Sakaguchi, Japan; Hiroko Segawa, Japan; Takashi Shigematsu, Japan; Tetsuo Shoji, Japan; Motoko Tanaka, Japan; Masatomo Taniguchi, Japan; Minako Wakasugi, Japan; and Suguru Yamamoto, Japan. Publisher Copyright: {\textcopyright} 2019 International Society of Nephrology",

year = "2019",

month = nov,

doi = "10.1016/j.ekir.2019.09.007",

language = "English",

volume = "4",

pages = "1523--1537",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - 2017 Kidney Disease

T2 - Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report

AU - Wang, Angela Yee Moon

AU - Akizawa, Tadao

AU - Bavanandan, Sunita

AU - Hamano, Takayuki

AU - Liew, Adrian

AU - Lu, Kuo Cheng

AU - Lumlertgul, Dusit

AU - Oh, Kook Hwan

AU - Zhao, Ming Hui

AU - Ka-Shun Fung, Samuel

AU - Obi, Yoshitsugu

AU - Sumida, Keiichi

AU - Choong, Lina Hui Lin

AU - Goh, Bak Leong

AU - Hao, Chuan Ming

AU - Kwon, Young Joo

AU - Tarng, Der Cherng

AU - Zuo, Li

AU - Wheeler, David C.

AU - Tsukamoto, Yusuke

AU - Fukagawa, Masafumi

N1 - Funding Information: This Summit conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Bayer HealthCare, Boehringer Ingelheim, Chugai Pharmaceutical, Fresenius Medical Care, Japan CKD-MBD Forum, Japanese Society of Nephrology (JSN), Kissei Pharmaceutical, Kyowa Kirin Pharmaceutical Development, Nikkiso, Ono Pharmaceutical, Suntop Healthcare, and Torii Pharmaceutical. We thank Dr. Sinee Disthabanchong for valuable input into this manuscript. Other conference participants are Ali K. Abu-Alfa, Lebanon; Hideki Fujii, Japan; Naohiko Fujii, Japan; Kunitoshi Iseki, Japan; Nobuhiko Joki, Japan; Tilakavati Karupaiah, Malaysia; Naoki Kashihara, Japan; Junichiro Kazama, Japan; Fumihiko Koiwa, Japan; Hirotaka Komaba, Japan; Braden J. Manns, Canada; Masahide Mizobuchi, Japan; Yusuke Sakaguchi, Japan; Hiroko Segawa, Japan; Takashi Shigematsu, Japan; Tetsuo Shoji, Japan; Motoko Tanaka, Japan; Masatomo Taniguchi, Japan; Minako Wakasugi, Japan; and Suguru Yamamoto, Japan. Publisher Copyright: © 2019 International Society of Nephrology

PY - 2019/11

Y1 - 2019/11

N2 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD) 2009 provided recommendations on the detection, evaluation, and treatment of CKD-MBD in patients CKD who are and are not undergoing dialysis. Because of the accumulation of evidence since this initial publication, the CKD-MBD Guideline underwent a selective update in 2017. In April 2018, KDIGO convened a CKD-MBD Guideline Implementation Summit in Japan with the key objective to discuss various barriers to the uptake and implementation of the CKD-MBD Guideline in 8 Asian countries/regions. These countries/regions were comparable according to their high-to-middle economic ranking assigned by the World Bank. The discussion took into account the availability of CKD-MBD medication therapies and government health policies that may influence reimbursement and practice patterns in the region. Most importantly, Summit participants developed a framework of multifaceted strategies aimed at overcoming barriers to guideline implementation. The Summit attendees suggested a shared decision-making approach between clinicians and patients in CKD-MBD management, as well as individualized care based on the treatment risk-benefit ratio. The Summit participants also discussed how KDIGO, as a guideline development organization, may work in partnership with local and national nephrology societies to provide education and facilitate implementation of the guideline by clinicians. The conclusions drawn from this Summit in Asia may serve as an important guide for other regions to follow.

AB - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD) 2009 provided recommendations on the detection, evaluation, and treatment of CKD-MBD in patients CKD who are and are not undergoing dialysis. Because of the accumulation of evidence since this initial publication, the CKD-MBD Guideline underwent a selective update in 2017. In April 2018, KDIGO convened a CKD-MBD Guideline Implementation Summit in Japan with the key objective to discuss various barriers to the uptake and implementation of the CKD-MBD Guideline in 8 Asian countries/regions. These countries/regions were comparable according to their high-to-middle economic ranking assigned by the World Bank. The discussion took into account the availability of CKD-MBD medication therapies and government health policies that may influence reimbursement and practice patterns in the region. Most importantly, Summit participants developed a framework of multifaceted strategies aimed at overcoming barriers to guideline implementation. The Summit attendees suggested a shared decision-making approach between clinicians and patients in CKD-MBD management, as well as individualized care based on the treatment risk-benefit ratio. The Summit participants also discussed how KDIGO, as a guideline development organization, may work in partnership with local and national nephrology societies to provide education and facilitate implementation of the guideline by clinicians. The conclusions drawn from this Summit in Asia may serve as an important guide for other regions to follow.

KW - CKD

KW - KDIGO CKD-MBD Guideline

KW - bone mineral density

KW - calcium

KW - dialysis

KW - hyperparathyroidism

KW - hyperphosphatemia

UR - http://www.scopus.com/inward/record.url?scp=85074216406&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2019.09.007

DO - 10.1016/j.ekir.2019.09.007

M3 - Article

AN - SCOPUS:85074216406

SN - 2468-0249

VL - 4

SP - 1523

EP - 1537

JO - Kidney International Reports

JF - Kidney International Reports

IS - 11

ER -

2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this